The addition of cyclin-dependent kinase (CDK) 4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) ushered in a new era in the treatment of metastatic HR-positive/HER2-negative BC [5]. The gene discussed is ERBB2; the disease is breast cancer.